update README and CHANGELOG

sigven · Aug 1, 2024 · 2ffebe2 · 2ffebe2
1 parent 61c42ce
commit 2ffebe2
Show file tree

Hide file tree

Showing 3 changed files with 18 additions and 2 deletions.
diff --git a/README.md b/README.md
@@ -28,6 +28,10 @@ PCGR originates from the [Norwegian Cancer Genomics Consortium (NCGC)](http://ca
 
 ### Top News
 
+- *August 1st 2024*: **2.0.3 release** 
+  - patch to fix purity/ploidy propagation, MAF output for tumor-only runs, and other minor issues
+  - [CHANGELOG](http://sigven.github.io/pcgr/articles/CHANGELOG.html)
+
 - *July 16th 2024*: **2.0.2 release** 
   - patch to ensure correct reference to actionability guidelines
   - [CHANGELOG](http://sigven.github.io/pcgr/articles/CHANGELOG.html)

diff --git a/pcgrr/pkgdown/index.md b/pcgrr/pkgdown/index.md
@@ -28,7 +28,10 @@ Example screenshots from the [quarto](https://quarto.org)-based cancer genome re
 PCGR originates from the [Norwegian Cancer Genomics Consortium (NCGC)](http://cancergenomics.no), at the [Institute for Cancer Research, Oslo University Hospital, Norway](http://radium.no).
 
 ### Top News
-
+- *August 1st 2024*: **2.0.3 release** 
+  - patch to fix purity/ploidy propagation, MAF output for tumor-only runs, and other minor issues
+  - [CHANGELOG](http://sigven.github.io/pcgr/articles/CHANGELOG.html)
+
 - *July 16th 2024*: **2.0.2 release** 
   - patch to ensure correct reference to actionability guidelines
   - [CHANGELOG](http://sigven.github.io/pcgr/articles/CHANGELOG.html)

diff --git a/pcgrr/vignettes/CHANGELOG.Rmd b/pcgrr/vignettes/CHANGELOG.Rmd
@@ -46,10 +46,19 @@ sigven <- user("sigven")
 pdiakumis <- user("pdiakumis")
 ```
 
+## v2.0.3
+
+- Date: **2024-08-01**
+- Ensure correct propagation of purity/ploidy in output report
+- Ensure that MAF output is properly filtered for tumor-only runs
+- Ensure properly copying of quarto templates (abandon `file.copy`), 
+both for PCGR and CPSR
+
+
 ## v2.0.2
 
 - Date: **2024-07-16**
-- Ensure correct reference to variant actionability guidelines - AMP/ASCO/CAP (*not* ACMG/AMP), both in code and in docs (thanks to [HomoPolyethylen] for pointing this out)
+- Ensure correct reference to variant actionability guidelines - AMP/ASCO/CAP (*not* ACMG/AMP), both in code and in docs (thanks to [HomoPolyethylen](https://github.com/HomoPolyethylen) for pointing this out)
 - fix bug in missing assignment of tier 3 variants (AMP/ASCO/CAP)
 - ensure non-exonic biomarker variants (e.g. TERT) are written to Excel sheet
 - specify (value boxes, plots) that MSI classification is based on coding variants